OGT’s CytoCell KMT2A Breakapart FISH Probe Kit received FDA de novo authorization as a companion diagnostic to identify acute leukemia patients with KMT2A gene translocations eligible for treatment with Syndax’s Revuforj. This innovation aims to improve patient stratification and outcomes in a hard-to-treat leukemia subset. Separately, researchers developed a novel PET tracer for same-day imaging of nectin-4 expressing triple-negative breast and urothelial cancers, promising enhanced rapid diagnostic capabilities to guide treatment decisions. These developments advance precision oncology diagnostic tools.